MYND MYND-604 Phase Ia Safety Trial

Mynd Life Sciences are hoping to begin Phase I of the clinical trial process investigating the application of MYND-604 in the treatment of major depressive disorder.

MYND-604 is a psilocybin formulation for which MYND has awarded patents.

Topic Depression
Compound Psilocybin
Country United States of America
Visit trial
Status Planned
Results Published
Start date 18 February 2022
End date 18 March 2023
Chance of happening 69%
Phase Phase I
Design Open
Type Interventional
Generation Second
Participants 30
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Mynd Life Sciences
Mynd aim to establish the link between depression and inflammation in the brain and ultimately therapeutically target this link using compounds found in psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.